For: | Loo JH, Xu WXF, Low JT, Tay WX, Ang LS, Tam YC, Thurairajah PH, Kumar R, Wong YJ. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World J Hepatol 2022; 14(6): 1248-1257 [PMID: 35978662 DOI: 10.4254/wjh.v14.i6.1248] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v14/i6/1248.htm |
Number | Citing Articles |
1 |
Pooja Devan, Kai Le Ashley Tiong, Jean Ee Neo, Babu P. Mohan, Karn Wijarnpreecha, Yew Chong Steve Tam, Nicola Coppola, Carmen Monica Preda, Yu Jun Wong. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis. Viruses 2023; 15(7): 1489 doi: 10.3390/v15071489
|
2 |
Abdullah S. Alghamdi, Hamdan Alghamdi, Haleema A. Alserehi, Mohammed A. Babatin, Khalid A. Alswat, Mohammed Alghamdi, Adel AlQutub, Faisal Abaalkhail, Ibrahim Altraif, Faleh Z. Alfaleh, Faisal M. Sanai. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024. Saudi Journal of Gastroenterology 2024; 30(Supp 1): S1 doi: 10.4103/sjg.sjg_333_23
|
3 |
Michał Brzdęk, Dorota Zarębska-Michaluk, Michał Kukla, Justyna Janocha-Litwin, Dorota Dybowska, Ewa Janczewska, Beata Lorenc, Hanna Berak, Włodzimierz Mazur, Magdalena Tudrujek-Zdunek, Jakub Klapaczyński, Anna Piekarska, Marek Sitko, Łukasz Laurans, Anna Parfieniuk-Kowerda, Robert Flisiak. Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices. Pharmacological Reports 2024; doi: 10.1007/s43440-024-00639-9
|
4 |
Vladislav Vladimirovich Tsukanov, Andrei Anatolyevich Savchenko, Mikhail Aleksandrovich Cherepnin, Eduard Vilyamovich Kasparov, Elena Petrovna Tikhonova, Alexander Viktorovich Vasyutin, Julia Leongardovna Tonkikh, Anna Alexandrovna Anisimova, Vasily Dmitrievich Belenyuk, Alexandr Gennadyevich Borisov. Association of Blood NK Cell Phenotype with the Severity of Liver Fibrosis in Patients with Chronic Viral Hepatitis C with Genotype 1 or 3. Diagnostics 2024; 14(5): 472 doi: 10.3390/diagnostics14050472
|
5 |
Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong. Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis. eClinicalMedicine 2024; 74: 102727 doi: 10.1016/j.eclinm.2024.102727
|
6 |
V. V. Tsukanov, A. A. Savchenko, M. A. Cherepnin, A. V. Vasyutin, E. V. Kasparov, V. D. Belenyuk, Ju. L. Tonkikh, A. G. Borisov. Subpopulation composition of blood T-helpers in hepatitis C patients with genotype 1 or 3. Meditsinskiy sovet = Medical Council 2024; (23): 168 doi: 10.21518/ms2023-447
|
7 |
Krystyna Dobrowolska, Michał Brzdęk, Piotr Rzymski, Robert Flisiak, Małgorzata Pawłowska, Jakub Janczura, Kinga Brzdęk, Dorota Zarębska-Michaluk. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals. Expert Opinion on Pharmacotherapy 2024; 25(7): 833 doi: 10.1080/14656566.2024.2358139
|
8 |
Wei Xuan Tay, Samantha Jingyun Koh, Francis Kok Ban Teh, Yu Bin Tan, Tian Yu Qiu, Linn War Mai, Vivien Li Xin Wong, Jessica Tan, Andrew Kwek, Kwong Ming Fock, Tiing Leong Ang, Rahul Kumar, Yu Jun Wong. Minimal monitoring is a safe but underutilised strategy for hepatitis C virus treatment in Singapore. Annals of the Academy of Medicine, Singapore 2023; 52(6): 321 doi: 10.47102/annals-acadmedsg.202347
|
9 |
Sergii V. Fedorchenko, Tatiana Martynovych, Zhanna Klimenko, Iryna Solianyk. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks. Journal of Clinical Virology Plus 2023; 3(2): 100150 doi: 10.1016/j.jcvp.2023.100150
|